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ADH = atypical ductal hyperplasia; cDNA = complementary DNA; CGH = comparative genomic hybridization; DCIS = ductal carcinoma in situ;
EGFR = epidermal growth factor receptor; ER = estrogen receptor; MALDI=matrix-assisted laser desorption/ionization; MS = mass spectrometry;
MS/MS = tandem mass spectrometry; PCR = polymerase chain reaction; SELDI-TOF MS = surface enhanced laser desorption/ionization time-of-
flight mass spectrometry.
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Introduction
Over the past 5–10 years, new high-throughput technolo-
gies have been developed and applied to breast cancer
research that facilitate genome-wide analyses of DNA,
RNA, and proteins. Through the global analysis of normal
and neoplastic breast tissue, these technologies have
identified tumor-specific molecular signatures and are
advancing research in breast tumor biology. They are
expanding our knowledge beyond that obtained from his-
tologic findings or studies of single genes. Consequently,
these technologies are now being incorporated into clini-
cal trials design. They offer the promise of improved diag-
nosis and prognostication and should assist in the
identification of molecular targets for future therapeutic or
preventive strategies, thereby improving our ability to care
for patients with, or at risk for, breast cancer.
Although these technologies were originally used to study
invasive breast cancer, they are now being extended to
pre-malignant and pre-invasive disease, facilitated by other
new technologies such as microdissection and nipple
duct aspiration, ductoscopy, and ductal lavage. Although
this field is still emerging, the results are encouraging and
should impact our understanding of breast cancer devel-
opment and progression.
Array-based comparative genomic
hybridization – DNA analysis
The genomes of breast tumors are characterized by
numerous chromosomal gains and losses (aneuploidy), as
well as more localized regions of gene amplification and
deletion. Such widespread DNA copy number alteration
may reflect ongoing chromosomal instability [1] or a tran-
sient instability that accompanies telomere crisis [2].
Regardless, the retained, non-random genomic DNA gains
and losses drive aberrant expression of oncogenes (e.g.
ERBB2) and tumor-suppressor genes (e.g. TP53), con-
tributing to the development and progression of cancer.
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The specific constellation of DNA copy number alterations
within a tumor or precursor lesion may provide biological
insight and prognostic/predictive value. Loss of heterozy-
gosity studies, which described allelic imbalances at spe-
cific loci on a chromosome, supported a genetic
relationship between precursor lesions and invasive breast
cancer [3,4].
Comparative genomic hybridization (CGH) was developed
in order rapidly to map DNA copy number alteration
across the genome [5]. In CGH, tumor and normal
genomic DNA are labeled with two different fluorophores
and co-hybridized onto normal metaphase chromosomes.
The ratio of fluorescence along each chromosome pro-
vides a cytogenetic representation of DNA copy number
changes in the tumor compared to normal sample. Unlike
karyotyping techniques, CGH does not require tumor
metaphases, and so can be readily applied to a solid
tumor specimen. Furthermore, the relative stability of DNA
allows for analyses of formalin-fixed, paraffin-embedded
tissues. Microdissection techniques, coupled with poly-
merase chain reaction (PCR) amplification of genomic
DNA using degenerate oligonucleotide primers, permit the
analyses of small, heterogeneous pre-invasive lesions.
Comparative genomic hybridization investigations have
advanced our understanding of presumptive precursor
lesions including hyperplasia of usual type and atypical
ductal hyperplasia (ADH) [6–9], lobular carcinoma in
situ [10] and ductal carcinoma in situ (DCIS), and have,
in particular, provided information about the transition
from DCIS to invasive carcinoma. Comparative genomic
hybridization data characterize DCIS as a genetically
advanced lesion with widespread DNA copy number
alteration [11,12]. Furthermore, common patterns of
alteration between DCIS and adjacent invasive lesions
support DCIS as a direct precursor of invasive breast
carcinoma [12,13]. Analyses with CGH also suggest the
existence of independent pathways of genetic evolution
within DCIS [12,14,15]. Well-differentiated DCIS is
characterized most frequently by loss of 16q and gain of
1q, while poorly differentiated DCIS displays localized
amplifications, frequently involving 11q13 (CCND1) and
17q12 (ERBB2). Interestingly, intermediately differenti-
ated DCIS appears to be a heterogeneous group, inclu-
sive of both genotypes. These data suggest that poorly
differentiated DCIS is not the final stage in an evolution
from highly differentiated DCIS, but rather that poorly
and highly differentiated DCIS are distinct genetic enti-
ties, separately evolving to invasive carcinoma. Similari-
ties in genomic alterations suggest that highly
differentiated DCIS is a precursor of more differentiated
invasive carcinomas, specifically tubulo-lobular, tubular,
and grade I invasive ductal subtypes, while poorly differ-
entiated DCIS is a precursor of grade III invasive ductal
carcinoma.
While CGH has provided important insight into the
biology of pre-invasive lesions, its ultimate usefulness is
limited by its cytogenetic mapping resolution. Array-based
CGH has recently provided a high-resolution alternative to
chromosome-based CGH [16–18]. In array CGH, tumor
and normal genomic DNAs are differentially labeled and
co-hybridized to a microarray comprising DNA elements of
known chromosomal location, typically either complemen-
tary DNAs (cDNA) or large genomic DNA inserts (e.g.
bacterial artificial chromosomes). The fluorescence ratio at
each element on the array reflects the relative copy
number for the corresponding DNA sequences in the
tumor compared to a normal sample. The mapping resolu-
tion provided is at least an order of magnitude higher than
chromosome-based CGH, and is limited only by the
number and genomic distribution of arrayed elements.
Array-based CGH also facilitates the parallel analysis of
gene copy number and gene expression [18].
The high-resolution mapping afforded by array CGH has
revealed in breast tumors a complexity of DNA copy
number alteration across chromosomes not previously
appreciated by conventional CGH [17,18]. As an
example, in an array CGH study of 44 locally advanced
breast tumors, several previously unrecognized regions of
recurrent amplification likely to harbor important cancer
genes were identified and precisely located [19].
Although no such studies have yet been reported for pre-
invasive lesions, we expect the improved spatial resolution
of genomic alterations afforded by array CGH to provide
additional insight into the molecular pathogenesis and pre-
cursor role of these lesions, to further clarify the transition
to invasive carcinoma, and perhaps to provide a basis for
earlier clinical diagnosis. For the characterization of pre-
invasive lesions, limited genomic DNA will be available
from microdissected specimens. Although one group has
reported performing array CGH using as little as 3ng of
genomic DNA [20], most array CGH protocols require
0.1–2.0µg  input DNA, and it is therefore likely that some
form of whole-genome amplification will be required for
the analysis of small cell numbers. It remains to be deter-
mined whether PCR with degenerate oligonucleotide
primers [21] can provide sufficiently unbiased whole-
genome amplification, or whether less biased methods
that do not rely on exponential amplification by PCR [22]
will prove more useful.
Expression profiling—RNA analysis
DNA microarrays permit the analysis of the relative expres-
sion level of thousands of genes in a single experiment.
Arrays can be membrane-based or slide-based. Nylon
membranes are spotted with cDNA clones and probed
with radiolabeled sample. Slide-based arrays are com-
posed of glass microscope slides specially treated with an
adherent such as polylysine or aminosilane. Glass arrays322
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can be spotted with over 40,000 cDNA clones or presyn-
thesized oligonucleotides using fine print tips or an ink jet
printer, or prepared with oligonucleotide probes synthe-
sized in situ using lithographic or ink jet technology. Slide-
based arrays, which are generally probed with fluorescent
dye-labeled sample, are smaller and easier to handle than
membrane-based arrays for high throughput, although
membrane-based arrays require less input RNA.
Tumor or breast tissue RNA is isolated from a snap-frozen
specimen. In contrast to DNA, which may be extracted
from tissue left at room temperature or from archival for-
malin-fixed tissue, RNA is less stable. Human tissue con-
tains ribonucleases that contribute to RNA degradation,
so the time between tissue devascularization and freezing
at –80°C may affect both the quality of RNA and the
genes that are expressed [23]. Tissue specimen of less
than 0.5cm thickness, such as core needle biopsies, may
be preserved at room temperature in solutions that perme-
ate the tissue and stabilize its RNA (e.g. RNAlater,
Ambion Inc., Austin, TX, USA, or RNAlater TissueProtect
Tubes, Qiagen Inc., Ventura, CA, USA). Recently, RNA
isolated from paraffin-embedded tissue has been tested
and compared to fresh specimen, generally on a gene-by-
gene basis using real-time quantitative PCR assays.
Studies on the suitability of paraffin-embedded RNA for
array-based examinations are ongoing [24]. Formalin
preservation of tissue causes RNA and protein cross-
linking that interfere with molecular analyses. In addition,
RNA hydrolysis and fragmentation occur at the high tem-
peratures required for paraffin embedding. Non-aldehyde-
based tissue fixatives, such as ethanol and methanol, and
low-melt polyester wax embedding compounds seem to
hold promise, although long-term nucleic acid or protein
stability are still in question and the performance of
immunohistochemical staining antibodies would require
reassessment. Recently developed commercial kits that
facilitate the isolation of RNA from formalin-fixed paraffin-
embedded tissues are undergoing testing.
For microarray experiments, either total RNA or mRNA is
isolated from an experimental sample. The RNA is reverse
transcribed to cDNA, directly or indirectly labeled with a
fluorescent dye, and hybridized to the microarray. If RNA
quantity is insufficient as a result of small tissue sample
size,  in vitro transcription-based linear amplification
[25,26] may be performed. This can generate enough
amplified antisense RNA, also known as complementary
RNA, for array hybridization. When using cDNA microar-
rays, a differentially labeled reference sample is used with
the experimental sample so that ratio measurements
cancel out differences in hybridization kinetics and quan-
tity of cDNA spotted on a given array. Total RNA, obtained
from cell lines that reproducibly express a majority of
human genes, may be used as a standard reference
sample that allows comparisons among multiple experi-
mental samples, even though they may be performed on
different days and with different array print batches. By
convention, the experimental (tumor) sample is labeled
with a red fluorophore (Cy5, which fluoresces at 635nm)
and the reference sample is labeled with a green fluoro-
phore (Cy3, which fluoresces at 532nm). Based on the
specificity and affinity of complementary base pairing, gene
expression for each cDNA clone on the array is captured
as signal intensities when the labeling dyes are fluoresced
at the two appropriate wavelengths in an optical scanner.
The measured signal intensities are normalized and a log
ratio of the normalized signal intensities for the experimen-
tal sample compared to reference for each spot on the
array is computed. This ratio essentially reflects the relative
abundance of a particular gene in the experimental sample
compared to the reference sample. The simultaneous mea-
surement of relative gene expression of thousands of
genes provides a genome-wide ‘portrait’ of gene expres-
sion for a tumor or other tissue. The data set is analyzed
using bioinformatics tools [27,28] to identify groups of
genes that may define subtypes within an experimental set
according to differences in their expression profiles. Corre-
lations of the subtypes with histologic or clinical parame-
ters are performed with the objective of identifying groups
of genes that may define characteristic features of a tumor.
Early studies of expression profiling of breast cancer were
performed on cell cultures and invasive breast cancers
[29,30]. Tumor specimens contained mixed cell popula-
tions: epithelial cells, stromal fibroblasts, vascular and lym-
phatic endothelial cells, adipocytes, and tumor-infiltrating
lymphocytes and macrophages. The important signaling
between epithelial and adjacent non-epithelial cells (tumor
microenvironment) was captured in the molecular profile
of the whole tissue, and gene expression of non-epithelial
populations could be distinguished. There are now multi-
ple studies evaluating expression profiles of invasive
breast cancer using different array technologies and on
different patient populations [31–34], including patients
carrying  BRCA susceptibility genes [35,36] and young
breast cancer patients [37,38].
Using their transcriptional profiles, invasive breast cancers
may be divided by molecular subtype into groups with dif-
ferent responses to systemic therapy and different survival
patterns [39]. Tumor gene expression patterns from
patients with locally advanced breast cancer, who were
similarly treated with doxorubicin followed by tamoxifen,
were distributed among five molecular subtypes. Two sub-
types, denoted luminal A and B, were characterized by
high relative expression of the estrogen receptor (ER)
gene and other ER-associated genes, and showed cyto-
keratin expression patterns suggestive of luminal epithelial
cell origin. The luminal subtypes comprised patients who
had long-term survival, in spite of their advanced disease
(luminal A), and patients with poor survival (luminal B),323
reflecting either differing tumor biology or differing
responses to systemic therapy, including possible tamox-
ifen insensitivity. The other subtypes showed relatively little
expression of ER-associated genes (most were ER-nega-
tive tumors) and were divided into three subtypes: an
ERBB2 overexpressing group, a basal epithelial-like group
(named for their high relative expression of basal cytoker-
atins), and a group that expressed normal-like genes,
including genes known to be expressed in adipose and
stromal tissue. The basal-like group (ER-negative and
without  ERBB2 overexpression) contained high-grade
tumors that were associated with high proliferation rates
and 82% harbored mutations in the TP53 gene. The
expression patterns of luminal, basal, and ERBB2-overex-
pressing tumors described in this study appear to corre-
late with the different tumor subtypes described by others
using CGH or immunohistochemistry [40,41].
Olopade and Grushko [42] suggest that tumors with
BRCA1 mutations may be consistent with a basal-like
pattern of gene expression because six out of seven tumors
from patients with BRCA1 mutations stained positive for
basal keratins and none showed ERBB2 overexpression.
They confirmed this in a larger study of BRCA1-associated
tumors that showed no or low ERBB2 amplification by fluo-
rescence in situ hybridization assays [43]. This is in con-
trast to tumors from patients with BRCA2 mutations that, in
a limited number, appeared to have a luminal, ER-positive
pattern. The findings of estrogen and progesterone recep-
tor negativity, lack of ERBB2 overexpression, and overall
higher grade in tumors from patients with BRCA1 muta-
tions, compatible with a basal-like molecular phenotype,
was confirmed by Lakhani and colleagues [44] in a larger
series of 217 patients with BRCA1 or BRCA2 mutations,
comparing them to 103 patients with sporadic breast
cancer. They also found that breast cancers caused by
BRCA2 mutations had immunohistochemical profiles
similar to sporadic breast cancers, although they were more
likely to be ERBB2 negative.
Based on the CGH work described above, it is anticipated
that noninvasive precursor lesions may be characterized
by similar molecular phenotypes as invasive breast cancer.
Expression profiling of pre-invasive lesions, however, is
technically more complex. First, it is difficult to freeze this
tissue prior to diagnosis. Atypical hyperplasias or DCIS
frequently present as non-palpable mammographic abnor-
malities (e.g. microcalcifications). Patient care necessi-
tates that the entire surgical biopsy specimen be analyzed,
without saving tissue for molecular analyses, for the fol-
lowing reasons: ADH and DCIS may be adjoining; DCIS
requires thorough histologic examination in order not to
miss areas of microinvasion; and margin status is vital for
treatment decisions if DCIS or microinvasive carcinoma is
identified. Therefore, the immediate freezing of surgical
biopsies of mammographic abnormalities is generally not
performed. However, with proper informed consent, addi-
tional core needle biopsies may be obtained at the time of
mammographic stereotactic or ultrasound-directed core
needle biopsy and frozen or stored in a commercial
reagent that preserves both tissue architecture and RNA
integrity. Using RNAlater (Ambion Inc.), Ellis and col-
leagues [45] were able prospectively to obtain sufficient
high-quality RNA for transcriptional profiling from preoper-
ative or postoperative core needle breast biopsies.
Laser microdissection may be used to isolate pre-invasive
lesions from adjacent ‘normal’ ductolobular tissue [46]. A
purified population of epithelial or stromal cells may be
obtained, and in conjunction with RNA amplification tech-
niques [47], expression profiling of the cells can be per-
formed. From a single modified radical mastectomy
specimen, Sgroi et al. [48] microdissected normal epithe-
lial cells, malignant invasive epithelial cells, and cells
metastatic to an axillary lymph node and used the RNA
from these specimens for studies on nylon membrane
arrays containing approximately 8000 genes. Verifying
gene expression with duplicate hybridizations, real-time
quantitative PCR and immunohistochemistry, they con-
firmed the feasibility and validity of this technique. Luzzi and
colleagues [49] compared the expression profiles of non-
malignant human breast epithelium and adjacent DCIS
microdissected from three breast cancer patients and iden-
tified several differentially expressed genes that had been
previously implicated in human breast cancer progression.
Adeyinka  et al. [50] compared six cases of DCIS with
necrosis (4 of high nuclear grade and 2 with intermediate
nuclear grade) to four cases of DCIS without necrosis (all
with low nuclear grade) using microdissection and 5544
spot membrane arrays. Similar to CGH studies, distinct
expression changes associated with DCIS grade and mor-
phology were found. Some of the genes that differed
between the two groups included those involved in cell
cycle regulation, signaling, apoptosis, and response to
hypoxia. In particular, the upregulation of AAMP, angio-
associated, migratory cell protein gene, in high grade
DCIS with necrosis was demonstrated using array tech-
nology, real-time PCR, and in situ hybridization – a gene
considered to function in migrating cells and which may
be hypoxia-mediated in tumors. The four DCIS samples
without necrosis demonstrated little gene expression vari-
ability, in contrast to the highly variable DCIS samples with
necrosis, and consistent with the hypothesis that low-
grade DCIS may represent a single molecular phenotype.
Ma  et al. [51] compared microdissected epithelial cells
captured from normal breast lobules, ADH, DCIS, and
invasive ductal carcinoma. They examined 39 breast spec-
imens, 36 containing cancer (5 of the 36 had DCIS only)
and three from reduction mammoplasties. Comparing
gene expression profiles of premalignant, pre-invasive, and
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invasive cells to normal cells isolated from the same speci-
men, but distant from the tumor, or from reduction mam-
moplasties, they observed no consistent major
transcriptional differences between ADH, DCIS and inva-
sive ductal carcinoma from the same specimen. There
were, however, distinct tumor signature differences
between low-grade and high-grade tumors. Grade II tumor
expression profiles were mixed, showing either low-grade
or high-grade signatures. This corroborates previous
limited data showing similarity between DCIS and invasive
breast cancer from Porter et al. [52] using serial analysis
of gene expression, and immunohistochemical data from
Warnberg et al. [53] suggesting that well differentiated
DCIS progresses to well differentiated invasive cancer
and that poorly differentiated DCIS progresses to poorly
differentiated invasive cancer. Ma et al. also showed that a
small subset of genes whose expression increased
between DCIS and invasive breast cancer, predominantly
in high-grade lesions, were related to cellular proliferation/
cell cycle regulation. Significantly, compared to normal
epithelium, ADH appeared to be a genetically advanced
lesion with an expression profile that resembled DCIS and
invasive breast cancer within the same specimen. This
study by Ma, Erlander, and Sgroi is the first to use tran-
scriptional profiling to demonstrate that ADH and DCIS
are direct precursors to invasive ductal carcinoma, con-
firming the work by Boecker [54,55] using double-
immunofluorescence staining techniques, which
suggested that ADH is a committed precursor lesion to
different molecular phenotypes of invasive breast cancer.
Analyzing data obtained using 16,000 gene oligo-
nucleotide arrays, Ramaswamy et al. [56] suggested a set
of 17 genes whose common expression across multiple
primary solid tumor types and their metastases identified
tumors with metastatic potential. van ‘t Veer et al. [37]
described a 70 gene prognosis profile in women less than
55 years of age that outperformed standard prognostic cri-
teria in a follow-up validation study [38]. One might hypoth-
esize that if (i) breast epithelial cells are committed to a
neoplastic subtype in the ADH stage, and (ii) gene expres-
sion profiles of pre-invasive lesions presage the molecular
phenotype of invasive cancers, and (iii) different molecular
phenotypes of invasive breast cancer vary in their clinical
outcome, then examination of pre-invasive lesions for unfa-
vorable expression signatures may distinguish breast tissue
that may ultimately evolve into metastatic breast cancer. By
eradicating more aggressive subtypes of pre-invasive
lesions using surgery, radiation, or targeted chemopreven-
tion, the development and clinical outcome of invasive
breast cancer might be favorably influenced.
Proteomics—protein analysis
Protein expression is the functional component that ulti-
mately determines cellular physiology. Analysis of RNA
expression alone cannot characterize all aspects of
protein expression; for example, proteins may undergo
post-translational modifications that can affect protein sta-
bility, activity, and subcellular localization. These differ-
ences may reveal important aspects of tumor biology.
Proteomics is the large-scale study of protein expression;
its tools and techniques are still under development. The
time-honored way of detecting proteins is by two-dimen-
sional (polyacrylamide) gel electrophoresis, which sequen-
tially separates proteins by their charge and molecular
weight. Using this method, Czerwenka and colleagues
[57] found multiple proteins differentially expressed in four
malignant breast tissue specimens when compared to four
normal tissue samples, including growth factor receptor
proteins. Two-dimensional gel electrophoresis is very labor
intensive and has limited resolution for the analysis of
large numbers of proteins. Each protein needs to be
excised from the gel, digested, and the peptide fragments
further analyzed using mass spectrometry (MS) or tandem
mass spectrometry (MS/MS). Two-dimensional liquid
chromatography, high-performance liquid chromatogra-
phy, or capillary electrophoresis use columns or multiple
capillary loops containing gradients to separate proteins
or protein digests on the basis of size and charge.
After protein or peptide separation, they must be ionized
into a protonated gas phase prior to MS analysis. Liquids
can undergo electrospray ionization and then MS or
MS/MS. The advantage of MS/MS is that peptides are
fragmented and then identified by specific amino acid
sequences. Solids are ionized by matrix-assisted laser des-
orption/ionization (MALDI) or surface-enhanced laser des-
orption/ionization (SELDI). MALDI is a technique that mixes
digested proteins with an organic acid matrix that catapults
the peptides into an ionized form when irradiated by an
ultraviolet laser. The peptides accelerate through an electri-
cal field in a time of flight MS, which separates them by
their mass to charge ratio (m/z). Reaching the detector at
different times, a peptide mass profile or fingerprint is
created that reflects the protein composition of the sample.
Proteins are identified by comparing the peptide mass fin-
gerprint to masses predicted by digestion of protein
sequences and published in large protein databases.
SELDI is another method [58] that captures proteins from
solubilized tissues or body fluids on diverse biochip sur-
faces using modified chromatographic techniques (affinity
capture) to fractionate and isolate proteins. At the surface of
the chip, retained proteins are combined with energy
absorbing molecules and pulsed with a laser into a time-of-
flight mass spectrometer. The use of different surfaces
creates different protein binding interactions and results in
different mass spectra. Since SELDI analyzes intact pro-
teins, it is not possible to identify individual proteins from the
mass spectra. Instead, each sample has a specific protein
fingerprint which then is related to clinical parameters.
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SELDI time of flight MS (SELDI-TOF MS) can be used to
analyze proteins secreted by cells lining or extruded into
the nipple ductal system. This would include secretions
produced by normal, hyperplastic, and preinvasive ductal
lesions. Sauter [59] found five differentially expressed pro-
teins that were present in 75–84% of samples from
women with invasive breast cancer but only 0–9% of
samples from normal women. Paweletz and colleagues
[60] found protein profiles that appeared to discern
women with breast cancer from healthy controls. Li et al.
[61] screened 169 serum samples from patients with
cancer, benign breast disease, or healthy controls using
SELDI-TOF MS. They identified a panel of three biomark-
ers that consistently separated stage 0–I breast cancer
patients from non-cancer controls. Wulfkuhle and col-
leagues [62] performed the first proteomic analysis of
matched normal ductal/lobular units and DCIS using laser
microdissected epithelial cells from frozen tissue sections,
which were separated by two-dimensional gel elec-
trophoresis and MS. The protein profiles of microdis-
sected epithelial cells differed from that produced from
whole tissue; both strategies were used to identify 134
unique differentially expressed proteins including intracel-
lular trafficking proteins and proteins involved in cell motil-
ity and genomic instability, suggesting that DCIS is an
already advanced preinvasive lesion.
Proteins may also be analyzed using a technology that
binds antibodies and/or antigens to glass microarrays.
Protein binding is measured by comparative fluorescence,
providing a high throughput enzyme-linked immunosorbent
assay [63]. Protein array assays may be performed using
biologic samples such as serum or plasma, nipple aspirate
fluid, cell lysates, or, potentially, for the analysis of surface
membranes of microdissected cells.
Newer activity-based protein profiling technologies (mea-
suring enzyme activity changes not just enzyme abun-
dance) suggest that specific enzyme activities may
correlate with degree of invasiveness by matrigel assay for
breast cancer and other tumor types [64]. This technique,
currently used to study primary invasive breast cancers,
may be applied to pre-invasive lesions if sufficient protein
can be isolated from microdissected cells. The measure-
ment of enzyme activities in precursor lesions may identify
high-risk lesions and offer insight in designing prophylactic
therapies that target specific molecular pathways to
prevent progression to an invasive or metastatic pheno-
type.
Clinical impact of new technologies
The diagnosis of pre-invasive breast lesions presents a
clinical dilemma for the patient and the physicians provid-
ing her care. Following a diagnosis of atypical hyperplasia
or DCIS, a patient is immediately considered high risk for
the future development of invasive breast cancer, although
this progression will only occur in a portion of patients.
Newer molecular technologies may define which patients
will develop invasive breast cancer and who are at high
risk for biologically aggressive disease. This could poten-
tially alleviate anxiety and screening costs for the patient
who is not at high risk. Molecular imaging technologies or
breast magnetic resonance imaging may be used to iden-
tify suspicious changes (e.g. hypoxia or angiogenesis) in
the breast tissue of high-risk patients [65]. Such patients
may benefit from systemic [66] or surgical prophylactic
therapies [67]. Targeting different molecular subtypes of
breast cancer precursor lesions will probably require dif-
fering strategies; for example, some precursor lesions
showing an ER-associated luminal subtype may respond
to prophylactic agents that block estrogen or its produc-
tion. Reduction in ER-positive invasive breast cancer by
tamoxifen has already been demonstrated in breast cancer
prevention trials [68]. Because basal-like invasive breast
cancers overexpress epidermal growth factor receptor
(EGFR) by immunostain [40] and expression profiling
[Jeffrey lab, unpublished data], EGFR antagonists may
prove to be a useful chemo-prophylactic therapy for pre-
cursor lesions with a basal-like molecular profile or for
women with BRCA1 mutations. A lack of response to
tamoxifen chemo-prophylaxis has been demonstrated in a
small number of women with BRCA1 mutations [69], sug-
gesting that agents useful in luminal precursor lesions do
not impact basal-like lesions. The EGFR tyrosine kinase
inhibitor ZD 1839 has already been shown to reduce
epithelial proliferation of ER-negative/EGFR-positive DCIS
implanted into immunosuppressed mice [70]. All of the
data above are consistent with differentiation pathway
commitment in the earliest pre-invasive stages of epithelial
neoplasia. Other questions remain: whether lesions of a
particular molecular subtype always herald invasive and
ultimately metastatic disease; and whether developing
invasive disease would be unifocal or multifocal/multicen-
tric, thereby influencing the type of prophylactic surgery
(lumpectomy versus mastectomy for excision of diseased
ducts before development of invasive cancer) and deci-
sions regarding chemo-prophylaxis. Another potential
treatment approach could be introduction of pharmaceuti-
cals via nipple duct catheterization, although intraductal
dye injection demonstrates that the fluid does not always
reach its intended site.
In order to link promising prognostic or predictive molecular
markers of pre-invasive lesions to clinical outcome, a high
throughput validation method is required. Tissue microar-
rays can be created from archival breast biopsies with long-
term clinical follow-up. Hundreds of pre-invasive lesions can
be inserted into a single paraffin block, which can be sec-
tioned and immunostained with a variety of markers [71].
Tissue microarrays may also be assayed using RNA in situ
hybridization techniques. Alternatively, markers may be vali-
dated by multiplexed quantitative PCR [72,73].
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Conclusion
The study of pre-invasive breast cancer using new tech-
nologies is still in its infancy. Array-based CGH provides
higher order resolution than standard CGH and can facili-
tate parallel analyses between copy number changes and
gene expression. This may help characterize malignant
transformation and the identification of different molecular
pathways that describe specific malignant phenotypes.
cDNA expression profiling has already defined different
molecular subtypes of invasive breast cancer that are
associated with different clinical outcomes. Expression
profiling of microdissected pre-invasive breast lesions
shows that ADH associated with invasive breast cancer is
already a genetically advanced lesion, with strong molecu-
lar similarities between ADH, DCIS, and invasive breast
cancer subtypes by CGH, cDNA microarray, and
immunostain analyses. Both array-based CGH and cDNA
microarray analyses should identify targets for future diag-
nostics and novel therapies. Proteomic studies are just
beginning to search for biomarkers that may form the
basis of future blood, nipple aspirate fluid, or tissue diag-
nostic tests so that women at risk, who may benefit from
close monitoring, systemic prophylaxis, or excision of dis-
eased ducts, may be identified well before the develop-
ment of any life-threatening malignant process.
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